An FDA approved neurokinin-1 receptor antagonist is effective in reducing intraabdominal adhesions when administered intraperitoneally, but not orally.
about
Efficacy and mechanism of tanshinone IIA liquid nanoparticles in preventing experimental postoperative peritoneal adhesions in vivo and in vitro.Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease.Current strategies and future perspectives for intraperitoneal adhesion prevention.Remote efficacy for two different forms of hyaluronate-based adhesion barriers.Combined intraoperative administration of a histone deacetylase inhibitor and a neurokinin-1 receptor antagonist synergistically reduces intra-abdominal adhesion formation in a rat model.Differential effects of aprepitant, a clinically used neurokinin-1 receptor antagonist on the expression of conditioned psychostimulant versus opioid reward.
P2860
An FDA approved neurokinin-1 receptor antagonist is effective in reducing intraabdominal adhesions when administered intraperitoneally, but not orally.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
An FDA approved neurokinin-1 r ...... aperitoneally, but not orally.
@en
An FDA approved neurokinin-1 r ...... aperitoneally, but not orally.
@nl
type
label
An FDA approved neurokinin-1 r ...... aperitoneally, but not orally.
@en
An FDA approved neurokinin-1 r ...... aperitoneally, but not orally.
@nl
prefLabel
An FDA approved neurokinin-1 r ...... aperitoneally, but not orally.
@en
An FDA approved neurokinin-1 r ...... aperitoneally, but not orally.
@nl
P2093
P1476
An FDA approved neurokinin-1 r ...... aperitoneally, but not orally.
@en
P2093
Adam C Gower
Jonathan M Morrill
Karen L Reed
Scott G Prushik
P2860
P2888
P304
P356
10.1007/S11605-008-0634-4
P577
2008-08-16T00:00:00Z